Aurobindo Pharma
AUROPHARMA · Pharma > Pharmaceuticals & Drugs · Chairman: K Ragunathan · MD: N Govindarajan · Listing date: June 14, 1995 · Employees: 19364 · Hyderabad · http://www.aurobindo.com

Stock Price vs Company Growth
1d
0.1%
1w
0.1%
1m
6.2%
3m
17.1%
6m
5.7%
1y
1.3%
5y
7.0%
10y
4.8%
all
16.9%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 1,223 0.1%
1,035
1,250
Company Overview

Sales
32,514 Cr
Growth: 7.8%
Profit after Tax
3,422 Cr
Growth: 0.9%
Large Cap
71,018 Cr
P/E: 20.7x
Industry P/E: 33.3x
Fundamentals

Sales (Cr) ₹ 32,514
Growth 7.8%
EBITDA 20.5%
P/S 2.2x
Dividend 0.0%
P/E 20.7x
Book Value ₹ 591
PEG Ratio 2.6x
ROE 10.3%
P/B 2.1x
Shareholding Pattern

Institutions
Life Insurance Corporation Of India
3.46 %
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund
3.4 %
Qualified Institutional Buyer
1.95 %
Nippon Life India Trustee Ltd-A/C Nippon India Pharma Fund
1.32 %
Bnp Paribas Arbitrage
1.22 %
Promoters
Rpr Sons Advisors Private Limited, Mrs.P.Suneela Rani (Jointly Holding)
33.51 %
K Nityananda Reddy
4.33 %
Kirthi Reddy Kambam
3.49 %
Venkata Ramprasad Reddy Penaka
3.07 %
Axis Clinicals Limited, Trident Chemphar Limited, Rpr Sons Advisors Pvt.Ltd. (Jointly Holding)
2.85 %
Others
Increase    Decrease    No change
Company Profile Detailed

Aurobindo Pharma is one of the leading vertically integrated formulations & API manufacturing companies in the world. It has a strong R&D focus and has a multi-product portfolio with manufacturing facilities in several countries. The company operates diversified businesses, structured to deliver targeted healthcare solutions across geographies and therapeutic areas. Its core operations are built on strong, integrated capabilities, encompassing both APIs and finished products.
Investors (197)
Followers (74)